Dose Optimization of Colistin Combinations against Carbapenem-Resistant Acinetobacter baumannii from Patients with Hospital-Acquired Pneumonia in China by Using an In Vitro Pharmacokinetic/Pharmacodynamic Model | Zendy

Xingchen Bian | Zendy; Xiaofen Liu | Zendy; Yuancheng Chen | Zendy; Daijie Chen | Zendy; Jian Li | Zendy; Jing Zhang | Zendy

Open Access

Dose Optimization of Colistin Combinations against Carbapenem-Resistant Acinetobacter baumannii from Patients with Hospital-Acquired Pneumonia in China by Using an In Vitro Pharmacokinetic/Pharmacodynamic Model

Author(s) -

Xingchen Bian,

Xiaofen Liu,

Yuancheng Chen,

Daijie Chen,

Jian Li,

Jing Zhang

Publication year - 2019

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.01989-18

Subject(s) - colistin , meropenem , acinetobacter baumannii , carbapenem , liter , pharmacodynamics , microbiology and biotechnology , pharmacology , pharmacokinetics , medicine , antibiotics , biology , pseudomonas aeruginosa , antibiotic resistance , bacteria , genetics

Colistin-based combination therapy has become an important strategy to combat the carbapenem-resistantAcinetobacter baumannii (CRAB). However, the optimal dosage regimen selection for the combination with maximum efficacy is challenging.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research